重度哮喘患者生物制剂疗效与吸烟状态:SHARP研究证据
基于ERS SHARP注册的回顾性真实世界研究,纳入16个欧洲国家3,876例重度哮喘成人,评估生物制剂治疗1年后应答与吸烟暴露的关系。四组(从不吸烟、既往吸烟<10包年、≥10包年、当前吸烟)症状控制、频繁急性发作、生活质量及口服激素使用均改善,组间变化幅度无统计学差异。SHARP调查显示29%参与国报告反对给当前吸烟者处方生物制剂,59%对现行指南不满。
要点
- 当前或既往吸烟的重度哮喘患者接受生物制剂1年应答与从不吸烟者相当。
- 四组均见症状控制改善、频繁急性发作减少、生活质量改善及口服激素使用减少。
- 不应仅因当前吸烟状态限制生物制剂处方,戒烟仍应是哮喘管理核心目标。
核心结论
- 重度哮喘吸烟者接受生物制剂治疗1年应答与从不吸烟者无统计学差异,提示限制吸烟者使用生物制剂的实践缺乏依据。
研究设计与样本
- 回顾性真实世界研究,数据来自ERS SHARP注册,应用OMOP通用数据模型,纳入16个欧洲国家3,876例重度哮喘成人,评估基线及生物制剂治疗1年后。
主要发现
- 3,876例中从不吸烟2,383例、既往吸烟<10包年540例、既往吸烟≥10包年812例、当前吸烟141例。
- 四组症状控制(ACT≥20/ACQ≤1.5)均改善,频繁急性发作(≥2次/年)均减少,哮喘生活质量(AQLQ)均改善,口服糖皮质激素使用均减少。
- 组间变化幅度无统计学差异,起始点有时不同。
- SHARP调查国家平均分析显示29%参与国报告反对给当前吸烟者处方生物制剂,59%对现行治疗指南表示不满。
临床怎么用
- 当前或既往吸烟的重度哮喘患者不应仅因吸烟状态被排除在生物制剂治疗之外。
- 吸烟管理仍应作为哮喘综合管理的核心目标,同时考虑尼古丁依赖的复杂性。
局限性
- 研究为回顾性真实世界设计,需在吸烟者中开展随机对照试验以获得更稳健且具包容性的科学结论与指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: The efficacy of biologics remains debatable in current or ex- smokers with severe asthma. OBJECTIVES: This study aimed to evaluate responses to biologics by smoking exposure and to assess variations in management practice across Europe. METHODS: This was a retrospective real-world study of adults with severe asthma from 16 European countries assessed at baseline and after 1-year of biologic treatment. Data were collected within the ERS SHARP (Severe Heterogeneous Asthma Research-Patient Centred) registry, applying the OMOP Common Data Model. MEASUREMENTS AND MAIN RESULTS: Of the 3,876 adult patients, 2,383 were never-smokers, 540 ex-smokers (<10 pack-years), 812 (≥10 pack-years), and 141 current-smokers. In all 4 groups, symptom control (ACT≥20/ACQ≤1.5) improved, frequent exacerbations (≥2/year) decreased, asthma quality of life (AQLQ) improved, and oral corticosteroid use decreased. While the starting point sometimes differed, the order of magnitude of change was not statistically different between groups. A country-averaged analysis of the SHARP survey revealed that 29% of participating nations reported opposition to prescribing biologics to current smokers, while 59% expressed dissatisfaction with current treatment guidelines. CONCLUSION: Our study reveals a lower prevalence of biologic therapy among adults with severe asthma who smoke and provides evidence suggesting this practice is unwarranted. Former/current smokers who underwent biologic therapy for one year responded as effectively as never-smokers. Recognising the complexity of nicotine dependence, smoking cessation should remain a central goal in asthma management. This study underscores the need for randomized controlled trials in smokers to enable more robust and inclusive scientific conclusions and guidelines.
引用
- Caminati M, Charriot J, Bansal AT, et al. Biologic outcomes in severe asthma patients by smoking status: evidence from SHARP. Am J Respir Crit Care Med. 2026. PMID: 42773700. doi:10.1093/ajrccm/aamag473
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。